BC Extra | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

Biotech fares better than markets in sell-off  U.S. biotech indexes fared slightly better than the broader markets Wednesday as stocks tumbled amid fresh signs of a global economic slowdown and a signal from bond markets...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Jun 8, 2018
Clinical News

Frontier's HIV drug approved in China

Frontier Biotechnologies Co. Ltd. (Nanjing, China) said China’s State Drug Administration approved once-weekly albuvirtide to treat treatment-experienced patients with HIV infection in combination with other antiretrovirals. The company said it is the first approved HIV...
BC Extra | Jun 5, 2018
Company News

Frontier's HIV drug approved in China

Frontier Biotechnologies Co. Ltd. (Nanjing, China) said China’s State Drug Administration approved once-weekly albuvirtide to treat treatment-experienced patients with HIV infection in combination with other antiretrovirals. The company said it is the first approved HIV...
BC Innovations | Jan 31, 2017
Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Patient sample and cell culture studies identified a chimeric, broadly neutralizing antibody (bNAb) against HIV gp41 that could help treat HIV infection. Thirty-five chimeric bNAbs were engineered by swapping the heavy...
BC Extra | Jan 6, 2017
Financial News

Frontier raises RMB300M in series C

Frontier Biotechnologies Co. Ltd. (Nanjing, China) said it raised RMB300 million ($43.2 million) in a series C round led by Huaxin Century. Shenzhen Capital, Efung Capital and undisclosed other investors also participated. Frontier said it...
BC Week In Review | Jul 11, 2016
Clinical News

Albuvirtide: Interim Phase III data

Interim data from 96 evaluable HIV-infected patients who failed first-line antiretroviral therapy (ART) in the modified intent-to-treat (mITT) population of the open-label, Chinese Phase III TALENT trial showed that once-weekly 320 mg IV albuvirtide plus...
Items per page:
1 - 7 of 7